Choosing the Best Approach for Patients With Favorable-Risk Metastatic Renal Cell Carcinoma

From the 18th International Kidney Cancer Symposium November 15-16, 2019, Miami, Florida Oncologists treating patients with favorable-risk metastatic renal cell carcinoma (RCC) have multiple choices, ranging […]

Evolving Landscape of the Treatment of Metastatic Clear Cell Renal Cell Carcinoma

Abstract: The management of advanced clear cell renal cell carcinoma (RCC) has evolved over the past decade with the introduction of targeted therapies and immune […]

Contemporary Management of Advanced Renal Cell Carcinoma

Abstract: Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease […]

Hem/Onc News

Rucaparib Approved for Maintenance Treatment in Recurrent Ovarian Cancer On April 6, the US Food and Drug Administration (FDA) approved rucaparib (Rubraca, Clovis Oncology) for maintenance […]

Cost-Effectiveness in the Surgical Care of Renal Cell Carcinoma

From the 16th International Kidney Cancer Symposium November 3-4, 2017, Miami, Florida When it comes to the surgical care of patients with kidney cancer, more is […]

How We Treat Brain Metastases in Metastatic Renal Cell Carcinoma

Overview • Brain metastasis in patients with metastatic renal cell carcinoma generally signifies a poor prognosis. • Surgical resection is an option for patients with […]

Current and Emerging First-Line Systemic Therapies in Clear Cell Renal Cell Carcinoma

H&O Which patients with clear cell renal cell carcinoma (RCC) are candidates for systemic therapy? BR All patients with clear cell RCC are potential candidates […]

Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma

Cabozantinib (Cabometyx, Exelixis) received an expanded indication from the US Food and Drug Administration (FDA) on December 19 as a first-line treatment in patients with advanced […]

Highlights in Kidney Cancer From the 2017 American Society of Clinical Oncology Annual Meeting

1From the 2017 American Society of Clinical Oncology Annual Meeting June 2-6, 2017 • Chicago, Illinois Adjuvant Pazopanib Does Not Extend Disease-Free Survival in Locally Advanced […]

Highlights in Kidney Cancer

Highlights in Kidney Cancer: From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 16-18, 2017 • Orlando, Florida Computer Assistance Reduces Errors in Evaluation […]

Combined Blockade of Vascular Endothelial Growth Factor and Programmed Death 1 Pathways in Advanced Kidney Cancer

Abstract: Targeted and immune-based therapies have improved outcomes in advanced kidney cancer, yet novel strategies are needed to extend the duration of these benefits and […]

The Future of Immunotherapy as Perioperative Therapy in Renal Cell Carcinoma

Reports from the International Kidney Cancer Symposium November 5-6, 2016, Miami, Florida Researchers are launching 2 new studies of checkpoint inhibitors as perioperative treatment for patients with […]

VEGF Inhibitors in Renal Cell Carcinoma

Abstract: The arrival of targeted therapies—vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors—and programmed death 1 (PD-1) inhibitors has […]

Kidney Cancer News

Cancer Vaccine Fails to Improve Survival in Metastatic Renal Cell Carcinoma The addition of the IMA901 multipeptide cancer vaccine to sunitinib (Sutent, Pfizer) did not […]

Adjuvant Treatment for Renal Cell Carcinoma: Do We Finally Have a Major Breakthrough?

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Devin N. Patel, MD, Robert A. Figlin, MD, and Hyung L. Kim, MD The […]